Oura Health postponed its $2.1 billion initial public offering Wednesday, halting what would have been the largest consumer hardware IPO since Rivian. The Finnish smart ring maker stated strong investor demand but cited prevailing market conditions in a brief press release. Shares were set to begin trading under ticker OURA on the New York Stock Exchange.
The company had priced its offering at the high end of the $18-$20 range earlier in the week, allocating 116.7 million shares. Lead underwriters Goldman Sachs and Morgan Stanley had built a book exceeding the offering size by Tuesday evening, according to two people familiar with the syndicate. Oura's revenue reached $547 million in the twelve months ending December 2024, representing 89% year-over-year growth, primarily driven by its Gen3 ring subscription model at $5.99 monthly.
The postponement follows Accelevation's 14% first-day decline on Monday and marks the third consumer tech offering to withdraw in ten trading days. Wearable device valuations have compressed sharply since Apple's Health subsidiary announcement in late March. Whoop, Oura's direct competitor, saw its private market valuation fall 22% in a secondary transaction last week, pricing at $2.8 billion versus a $3.6 billion mark in October. The broader consumer electronics sector trades at 2.1x forward revenue, down from 3.4x in January, pressured by tariff uncertainty and inventory build concerns.
The timing matters for capital formation in health-focused consumer hardware. Oura had planned to use $780 million of proceeds to fund manufacturing expansion in Vietnam and accelerate FDA clearance for its atrial fibrillation detection feature, expected in Q3 2025. The company generates 73% gross margins on hardware and 91% on subscriptions, but carries $340 million in convertible notes from its 2023 Series D at a $3.2 billion post-money valuation. Those notes include ratchet provisions triggered if the IPO prices below $2.5 billion enterprise value.
Allocators should watch for three follow-on events. First, whether Oura returns to market in the June IPO window, which would require refiling its S-1 amendment within 45 days. Second, the Apple Health subsidiary's product announcement, rumored for late May, which will clarify competitive positioning. Third, any secondary market activity in Whoop or Fitbit-adjacent private assets, which will establish the wearable tech valuation floor. The company's underwriters retain a 90-day option to re-launch without penalty.
Oura's installed base reached 2.4 million rings as of December, with 68% of users maintaining active subscriptions beyond twelve months. That cohort retention supports a $4.2 billion lifetime value calculation at current churn rates, but the multiple depends entirely on whether public markets will pay for recurring revenue in a commodity hardware category.